Slide 1: IN8bio, Inc.
IN8bio, Inc. | +1 646.600.6GDT (6438) | info@IN8bio.com | www.IN8bio.com
Slide 2: Disclaimer
Disclaimer The material in this presentation (this “Presentation” regarding IN8bio, Inc. (“we”, “us” or the “Company”) is for informational purposes only. This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, that involve su
Slide 3: IN8bio Leading the Fight Against Cancer
IN8bio Leading the Fight Against Cancer • • • γδ • • γδ • •
Slide 4: γδ T Cells are Key to Better Survival
v5 T Cells are Key to Better Survival Leukemia Post-HSCT: Improved Patient Survival Overall Survival 1.04 0.84 76 High 70.8% 0.64 oad 76 Low 19.6% 0.24 p=<0.0001 0.04 0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 Years Pan-Cancer: Improved Patient Overall Prognosis Pan-cancer Solid tumors (25 malignancies
Slide 5: IN8bio's Thesis for a Successful Cellular Therapy
IN8bio’s Thesis for a Successful Cellular Therapy Our three-pronged approach to targeting cancers: Durability Meaningful © ureton oF response can be achieved by increasing the depth oF response through novel synergistic combinations. INSbio Tolerability Utilize nove! cell types witha natural ability
Slide 6: Robust Pipeline with Multiple Near-Term Clinical Readouts
Robust Pipeline with Multiple Near- Term Clinical Readouts Product Candi Siem Preclinical Phase 1 Phase 2 Phase 3 late Approach —_Key Indi Hematologic Malignancies (Allogeneic) + Provide LT follow-up, enroll patients and report updates in expansion cohort at DL 2 through INB-100 DeltEx ‘AML, MDS rT
Slide 7: Overview of γδ T Cells
Overview of y5 T Cells
Slide 8: γδ T Cells — Leveraging the Nexus of the Immune System
y5 T Cells — Leveraging the Nexus of the Immune System Natural Kilor 3 Colt Ew) # % Dendritic Cell BCell Alpha-Beta Innate Immune Response Metcall - TCell Adaptive Immune Response ( ’ oman) © Macrophage T Cell “| (*) ¢ NN Complement 4 Protein Natural itor antwodies \*) (*) oy oH \ cote ces %® @O@8 ‘
Slide 9: Multiple Weapons, Multiple Targets for Cancer Treatment
Multiple Weapons, Multiple Targets for Cancer Treatment Sensing Cellular Stress with Gamma-Delta T cells Effector Functions of Gamma-Delta T cells Harget Gell Gamame-Delta Cell Activated Gamma-Delta T Cell Tumor Cell ‘Stress-induced NKG receptors @ TRAIL Death Receptor 4/5 NKG20 O95 >) ¥ XX iz Cytot
Slide 10: γδ T Cells Possess Unique Capability to Distinguish Healthy Cells
y5 T Cells Possess Unique Capability to Distinguish Healthy Cells Innate Adaptive Missi Healthy Self oP T cell ==) pangerous | cell non-Self 4 Anti CAR No-Kill Potentially widens the therapeutic index, which will be required to successfully target solid tumors . INSbio ours Aca om Hayy a, Cana ta T
Slide 11: Our DeltEx Platform
Our DeltEx Platform v5 T Cell Engineering and Manufacturtag y?' ’;
Slide 12: Manufacturing Primary γδ T Cells
Manufacturing Primary y6 T Cells Clinical Manufacturing for INB-100, -200, -400 + Automated, robust and scalable cell manufacturing in a single, closed system to increase output and reduce risks of contamination * Designed for efficient scaling for clinical trials and commercial capabilities * IN8bi
Slide 13: Manufacturing iPSC γδ T Cells
Manufacturing iPSC y6 T Cells yor VoITIPSC VO2T-iPSC Co) 7 ipsc a program Wy ( «e Differentiation =) a Se oo, Be) . STAGE 1 (y5 T-iPSC generation) Expansion & Clonal Characterization STAGE 3 Selection Disease Specific Multi-step Gene-edits differentiation STAGE 2 [ meee preacess fom yoeT- WOW, ~ f l
Slide 14: IN8bio Possesses a Comprehensive γδ T Cell Platform
IN8bio Possesses a Comprehensive y6é T Cell Platform y6 T Cell Sourcing Cin: IN Sbio ‘Source: IN8bio, image created with Shutterstock and biorender.com Tumor Targeting Hematological Cancers 14
Slide 15: INB-100
INB-100
Slide 16: Post-Transplant Survival Supported by Outside Research
Post-Transplant Survival Supported by Outside Research Improved Survival Improved Overall Survival, wot at, z ia Hey % Relapse-Free-Survival, and Less 7 ae 4 ta Graft-vs.-Host-Disease in Patients “oy =. = With High Immune Reconstitution of 2” tare Pa “i TCR Gamma Delta Cells 2 Months 2. L. i After A
Slide 17: Key Personnel
Key Personnel • • 1 year 2 years 1 year 2 years • γδ • γδ
Slide 18: INB-100: An Allo Therapy to Reduce Leukemic Relapse
INB-100: An Allo Therapy to Reduce Leukemic Relapse Single-center, dose-escalation trial of DeltEx Allo gamma-delta T cells post-haploidentical HSCT ef8 Treatment Arms fi] Treatment Regimen & Timing fB) Key Eligibility Criteria @ Primary Endpoints Q Secondary Endpoints oT IN 6 bio *RP2D = Recommende
Slide 19: Potential to Provide Protection During a Vulnerable Period
Potential to Provide Protection During a Vulnerable Period Expanded + activated gammaz-delta T cells (EAGD) to prevent leukemic relapse 2 Graft 1 BM (CD34+) _ Host Immune Pad Cells a Immune Reconstitution HSCT Derived ' i Immune Cells Gamma- U Delta T Cell ia Haplo CD34+ Infusion | | infusion 1 Prep
Slide 20: Patient Demographics and Summary
Patient Demographics and Summary Dose | Age/ Prior Therapies Disease Acute / Chronic GvHD Level | Sex Average patient age ~68 y/o 63/ - High-risk AML trisomy 8+ Acute G2 skin GVHD : 002 1 female Idasanutlin + 743 eel FLT3 TKD Chronic limited mild skin 51.6+ Alive , GvHD Majority have AML 44/ High-ri
Slide 21: Subjects Enrolled
Subjects Enrolled Death due to Idiopathic Pulmonary Fibrosis (IPF), not progression* Extramedullary relapse Note: *POD = progression of disease; *As of August 1, 2024; Early trial results are not indicative of future results, including the outcome of this trial.
Slide 22: na na na
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ na ✓ ✓ ✓ na ✓ ✓ na ✓ ✓ ✓ ✓ na ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ na ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Note: *As of May 31, 2024; Early trial results are not indicative of future results, including the outcome of this trial.
Slide 23: One-Year In Vivo Persistence and Expansion of γδ T Cells
One-Year In Vivo Persistence and Expansion of y6 T Cells 80000 60000- 40000- y5 T Cells/mL INSbio Haplo-Cy vs INB-100 mmm HaploCy ma Cohort 1 mal Cohort 2 Days post BMT/group Source: IN8bio, Inc. and UAB “previously unpublished data from laboratory of Dr. Lawrence Lamb; as of August 1, 2024 Comparis
Slide 24: Registrational Trial Design
Registrational Trial Design
Slide 25: Registrational Phase Trial
Registrational Phase 2 Trial y5 T Cells Maintenance Therapy in AML Patients Undergoing Haploidentical Transplant N~287 Arm A: Experimental n=191 Primary Endpoint: * Adult AML patient with RIC Haploidentical transplant with post-transplant R aa - + Relapse Free lnglo cis tteetnnes tin Ci) cyclophosph
Slide 26: INB-300
INB-300 Novel nsCAR yé T Cell Platform
Slide 27: A Unique CAR-T Platform that Spares Healthy Tissue
A Unique CAR-T Platform that Spares Healthy Tissue Novel Non-Signaling y& CAR-T Platform (ns-CAR) ns-dCAR-mb15 y6 T Cell ns-dCAR-mbIL1S viral vector Specific Kill * y6 T cells have a broad-based MHC unrestricted receptor repertoire that can identify and distinguish healthy from stressed cells (infec
Slide 28: CD123+ CD33+ CD123+
CD123+ CD33+ CD123+ CD33+ CD123+ AML CD33+
Slide 29: ns-γδ T CARs Do Not Increase Killing vs. Healthy Cells
ns-y6 T CARs Do Not Increase Killing vs. Healthy Cells Presented at AACR 2024 - CD34+ HPC, HL-60, KG-1a, MOLM-18 are all CD38+ cells * Cytotoxicity of nsIL3- UTD-y5T vs ns33CAR-y5T constructs 33mb15 nsCAR against 24h co-culture AML cell lines was 5.5x me I KGa Il MOLM-13. Il {cosa | greater than aga
Slide 30: Targeting Solid Tumor Cancers
Targeting Solid Tumor Cancers
Slide 31: Shortfalls of Conventional Cell Therapies in Solid Tumors
Shortfalls of Conventional Cell Therapies in Solid Tumors CAR-Ts have demonstrated efficacy in blood cancers but have not had similar results in solid tumors GF aA © OQ K 4 Tumor T Cells unable to Few targets that Immune- Trafficking of T | Chemotherapy kills heterogeneity penetrate tumor can be abl
Slide 32: Targeting Cancers by Driving Deeper Responses
Targeting Cancers by Driving Deeper Responses Progressive Disease Tumor Burden Durable Response Time y6 T cells Genetically Engineered to Survive Chemotherapy Induced Cell Death le 32 Source: Adapted from Madan et al. Sem in Onc. 2012, Vol 39, No 3 and Ribaset al. Clin Canc Res, 18(2), Jan. 2012
Slide 33: Overcoming Challenges to Targeting Solid Tumors
id Tum ing Challenges to Targeting Sol Overcom
Slide 34: Versus: Chemo-resistant GBM lines / Glioma stem-like cells
Versus: Chemo-resistant GBM lines Versus: Glioma stem-like cells
Slide 35: Targeting the DDR Pathway Eliminates Residual GBM
Targeting the DDR Pathway Eliminates Residual GBM wrreaes TMZ + DRI gamma-delta T cells treated - surviving mice (n=8) +14 days : : 4) ee = & << a — aa ae TMZ treated at sacrifice Y - Long-Term Survival (+150 days) Figure 4: Digital light microscopic images from athymic nude mice that received intra
Slide 36: INB-200
INB-200 DeltEx DRI Auto for GBM >
Slide 37: Pursuing Treatment in GBM: Following the Biology
Pursuing Treatment in GBM: Following the Biology The biology shows us the multiple advantages of yé T cells in the solid The brain offers a separate compartment tumor setting, particularly in that allows direct delivery of cells through lioblastoma, where patients have a catheter directly to the sit
Slide 38: INB-200: Study Design and Treatment Schema
INB-200: Study Design and Treatment Schema ef8 Treatment Arms (8 Treatment Regimen & Timing @ Primary Endpoints @ Secondary Endpoints } Site INSbio” sos mune Fixed dose level (DL) of DRI in a 3+3 design (N=18): = 3 (up to 6) patients, single dose of 1 x 10’ cells on C1D1 (up to 6) patients, three do
Slide 39: Poor Survival and Standard of Care Hasn't Changed in Years
Poor Survival and Standard of Care Hasn’t Changed in 18 Years Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma Roger Supp, M.D, Wa ‘Brandes, MD, Chi M0, Alban N=573 Median age 56 (range 19-71) PS 2 only 12% RT+TMZ median OS 14.6 months RT+TMZ median PFS 6.9 months (95% Cl 5.8
Slide 40: Demographics and Efficacy
Demographics and Efficacy fees owree] owner] Es [nm Median age: 68 68/M —_ IDH-WT, MGMT-unmethylated Total biectom vps + 54% unmethylated 003 74/F IDH-WT, MGMT-methylated 1 Total 6 sD 11.9 17.7 004 21/F — IDH-WT, MGMT-unmethylated 1 Total 3 sD 7A 9.6 * 23 enrolled, five Hl products unable to be 007
Slide 41: Patient 009 — Surpassing Expectations for IDH-mut Glioma
Patient O09 — Surpassing Expectations for IDH-mut Glioma The NEW ENGLAND JOURNAL of MEDICINE | RESEARCH SUMMARY | Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma Mellinghoff IK et al. DOI: 10.1056/NEIMoa2304194 Progression-free Survival HR for disease progression or death, 0.39 (95% Cl, 0.27-0.
Slide 42: Subjects Enrolled
A B Death due to sepsis Death due to cardiac arrest without progression Subjects Enrolled Death due to pulmonary embolus without progression POD due to leptomeningeal disease Note: *Of Evaluable Subjects; POD = progression of disease; As of August 1, 2024; Source: ^NEJM 2005; 352:987-996 & 352:997-1
Slide 43: Patient — Female 77y, IDH-wt, MGMT-methylated
Patient 017 — Female 77y, IDH-wt, MGMT-methylated Remains alive and relapse-free at 12.7+ months; “Demonstrated continued slight decrease in size of heterogenous enhancing lesions and decrease in size of nodular enhancing component” Surgical resection and 05.16.23 08.02.23 Diagnosis GBM confirmation
Slide 44: γδ T Cells are Infiltrating and Persisting in Tumor Tissue
v5 T Cells are Infiltrating and Persisting in Tumor Tissue Preserved y6 cells in relapsed tumor 148 days post-DRI infusion * despite significant peripheral lymphodepletion in patient 001 INB-200 Absolute Count: T cell 2750000: ppaneccceceeeeccecccecccccccccccccccccceceeeeeeseeeseeeteeee 1750000 2500
Slide 45: Phase 2 – Arm A Enrolling Newly Diagnosed GBM Patients
Phase 2 – “Arm A” Enrolling Newly Diagnosed GBM Patients
Slide 46: INB-400: Study Design and Treatment Schema
INB-400: Study Design and Treatment Schema Autologous: Confirms INB-200 signal | Phase2 * Auto DRI T cells + 150mg/m? IV/PO TMZ C1 and 200mg/m? C2-6 TMZ q28days —— > Primary * N=40 Endpoi * Phase 1: MTD Allogeneic Phase 1b + Phase 2: + Arm B*: Relapsed GBM pts - Arm B:9 mos ion i OS Rate * Allo DRIT
Slide 47: INB-400: Enrolling Centers - NCT05664243
INB-400: Enrolling Centers - NCT05664243 Company/Hospital/Institution City (Investigator) 1 University of Alabama at Birmingham (UAB) - The Kirklin Clinic Birmingham, AL 2 Cleveland Clinic Foundation Cleveland, OH 3 H. Lee Moffitt Cancer Center and Research Institute Tampa, FL 4 OSU Wexner Medical C
Slide 48: Corporate
Corporate
Slide 49: Deep Experience Across Development and Biotechnology
Deep Experience Across Development and Biotechnology William Ho Lawrence Co-Founder, Lamb, PhD President and Chief Co-Founder and Executive Officer Chief Scientific Officer Patrick . | Trishna McCall, CPA Goswami, MD Chief Financial Chief Medical Officer Officer Kate Rochlin, Glenn Schulman, PhD Pha
Slide 50: IN8bio Key Advisors
IN8bio Key Advisors Board of Directors Alan illi Corinne Emily Jeremy Luba Travis ®Y Roemer igi Epperly, Fairbairn Graff, Greenwood, Whitfill, coe b MD Member PhD JD , MPH Member q Member Member Member Scientific Advisory Board Siraj Ali, MD, Michael Dieter Bruce Marcela Bianca PhD Bishop, Kabelitz,
Slide 51: Balance Sheet
2023 2H INB-100 Balance Sheet INB-200 INB-300 • • INB-400 • INB-500 2024 INB-100 • • INB-200 • • INB-300 INB-400 CONFIDENTIAL
Slide 52: Patent Family
• Patent Family #6 Compositions and Methods for Treating Cancer ▪ ▪ γδ • Patent Family #3 Methods for Stem Cell γδ Transplantation
Slide 53: Harnessing the Power of Gamma-Delta (γδ) T Cells
Harnessing the Power of Gamma-Delta (v8) T Cells... Unique Platform We are using yé T cell therapy in a differentiated way, focusing on synergistic combinations Approach based on biology unique to yé T cells Most comprehensive in the industry, with proprietary genetic engineering and cell-type speci
Slide 54: Harnessing the Power of γδ T Cells
Harnessing the Power of y6 T Cells
Slide 55: The Unmet Need in Oncology Trials is Significant
The Unmet Need in Oncology Trials is Significant “When | was first diagnosed with AML, we (my wife and |) were updating the will and planning for the worst. Dr. McGuirk and his team discussed the gamma-delta clinical trial and asked if | wanted to participate. | was hoping for a cure, but I figured
Slide 56: Join Us on Our Mission to Achieve Cancer Zero
Join Us on Our Mission to Achieve... Cancer Zero. Connect With Us! ro ‘www.in8bio.com ee ros aes @in8bio eel 080000